DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

- DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disease control - - Offers longest dosing option for HAE, with dosing every 4 or 8 weeks - - Compelling profile supported by recently published switch data - - Ionis’ second independent launch in just nine months, with potential for two additional launches next year - - Ionis to host webcast today at 12:15pm ET - CARLSBAD, Calif.--(BUSINESS WIRE)--Aug. 21, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is the first and only RNA-targeted medicine approved for HAE, designed to target plasma prekallikrein (PKK), a key protein that activates inflammatory mediators associated with acute attacks of HAE. DAWNZERA 80mg is self-administered via subcutaneous autoinjector once every four (Q4W) or eight weeks (Q8W). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250818615141/en/

The release as fetched from its publisher. ionis.com ↗